Pericarditis News and Research

RSS

Pericarditis is defined as the state of inflammation or infection of the pericardium, the membranous sac that encloses the heart. The cause and severity of pericarditis determines the type of treatment appropriate for this condition.

COLCORONA study shows that colchicine can reduce complications in certain COVID-19 patients

The Montreal Heart Institute announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.

28 May 2021

Inflammatory heart disease is rare among professional athletes with mild COVID-19, study finds

Inflammatory heart disease is a rare finding among professional athletes with mild or asymptomatic COVID-19 infection, a large-scale study has found.

4 Mar 2021

Can early use of colchicine reduce COVID-19 mortality?

The COVID-19 pandemic, caused by SARS-CoV-2, has caused well over 2.3 million deaths in a little over a year. A new meta-analysis reports the potential utility of colchicine in treating SARS-CoV-2 infection and forestalling severe and life-threatening inflammation of the lungs and other organs.

8 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease

"But it's a marathon whereas you keep going, the trail gets rockier and then you lose your shoes," the 27-year-old said. "It gets harder as you get older. Things start to fail and all you can think about is how much worse it's going to get down the road."

1 Dec 2020

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Now, in new research, the everyday painkiller aspirin will be evaluated as a potential treatment for COVID-19 in one of the United Kingdom’s most significant trials, aiming to evaluate whether it can reduce the risk of blood clots in infected people.

9 Nov 2020

Study indicates the relationship between SARS-CoV-2 viral infection and diabetes

It has recently been described that infection by some enteroviruses - a genus of viruses that commonly cause diseases of varying severity - could potentially trigger diabetes, although its direct effect 'in vivo' as well as its mechanism of action at the molecular level were unknown.

21 Oct 2020

Severe and fatal COVID-19 is rare in children

Now, a new study by researchers at the Universities of Edinburgh and Liverpool, Imperial College London, and the Royal Hospital for Children, Glasgow in the United Kingdom has shown that children and teenagers are less likely than adults to develop severe COVID-19 or die from the disease.

30 Aug 2020

Study shows how picornaviruses infect the host cell

Picornaviruses is a family of viruses that can cause a number of different diseases, including polio, meningitis, and in rare cases myocarditis, encephalitis, and paralysis.

13 Aug 2020

COVID-19: What the illness looks like

With increasing information about COVID-19 disease gathered first-hand, a more accurate picture of the clinical features is coming together.

2 Apr 2020

Rheumatoid arthritis linked to other diseases, finds new study

A study found that risk of developing rheumatoid arthritis is higher in people with certain diseases.

21 Nov 2019

Cancer survivors could be at greater risk of cardiovascular diseases

Over the last few decades, medical progress has led to the survival of many more people with cancer. However, a new study published in The Lancet shows that this cohort has a higher risk of cardiovascular disease (CVD) than controls without cancer, due to a number of reasons.

21 Aug 2019

Study shows potential culprit behind Lupus

A team of researchers at the Emory University School of Medicine show that patients with SLE or lupus, have abnormal activation of B cells, which is part of the body’s immune system

8 Jul 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Pericarditis News and Research

Further Reading

COLCORONA study shows that colchicine can reduce complications in certain COVID-19 patients

Inflammatory heart disease is rare among professional athletes with mild COVID-19, study finds

Can early use of colchicine reduce COVID-19 mortality?

Colchicine may have therapeutic potential against COVID-19

Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Study indicates the relationship between SARS-CoV-2 viral infection and diabetes

Severe and fatal COVID-19 is rare in children

Study shows how picornaviruses infect the host cell

COVID-19: What the illness looks like

Rheumatoid arthritis linked to other diseases, finds new study

Cancer survivors could be at greater risk of cardiovascular diseases

Study shows potential culprit behind Lupus

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News